A
Alto Neuroscience, Inc. (ANRO)
NYQ – Real Time Price. Currency in USD
27.04
+1.74 (6.88%)
At close: Jun 26, 2026, 4:00 PM EDT
26.50
-0.54 (-2.00%)
After-hours: Jun 26, 2026, 5:55 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
27.04
+1.74 (6.88%)
At close: Jun 26, 2026, 4:00 PM EDT
26.50
-0.54 (-2.00%)
After-hours: Jun 26, 2026, 5:55 PM EDT
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson’s disease for patients with Parkinson’s disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
| Name | Position |
|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, CEO & President |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer |
| Mr. Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder & Strategic Advisor |
| Mr. Michael C. Hanley M.B.A. | Chief Operating Officer |
| Mr. Nicholas C. Smith | CFO & Chief Business Officer |
| Ms. Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer & Corporate Secretary |
| Ms. Jessica Powell | Chief Development Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-28 | 8-K | alto-20260527.htm |
| 2026-05-13 | 8-K | alto-20260513.htm |
| 2026-05-13 | 10-Q | alto-20260331.htm |
| 2026-04-17 | CORRESP | filename1.htm |
| 2026-04-10 | S-3 | tm2611320-1_s3.htm |
| 2026-04-01 | 8-K | tm2610746d1_8k.htm |
| 2026-03-26 | DEFA14A | tm264616d3_defa14a.htm |
| 2026-03-26 | DEF 14A | tm264616-1_def14a.htm |
| 2026-03-16 | 8-K | alto-20260316.htm |
| 2026-03-16 | 10-K | alto-20251231.htm |